Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer… (NCT06842056) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
Multinational Observational Study to Describe Diagnostic Stage Shift in Patients With Lung Cancer Using Medical Records
3,000 participantsStarted 2027-04-01
Plain-language summary
Multinational observational study to describe diagnostic stage shift in patients with lung cancer using medical records. Increased lung cancer screening programs and increased utilization of other screening modalities such as large increase in community chest radiography referral rates in response to public awareness campaigns, as well as unintentional detections through cardiac CT(computed tomography) angiograms, or screening for coronary disease may help in detecting the disease at earlier curable stages. Availability and increased access to novel therapies increase the likelihood of an early-stage diagnosis aiming for improved survival.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Adult female and male patients ≥18 years old.
* Confirmed diagnosis of lung cancer (either cytologically or histologically)
Exclusion Criteria:
* Patients presenting with recurrent or relapsed lung cancer.
* Patients with a concomitant cancer at the time of diagnosis of lung cancer, except for nonmetastatic nonmelanoma skin cancers, or in situ or benign neoplasms: a cancer will be considered concomitant if it occurs within 5 years of lung cancer diagnosis.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This study is described as 'observational' and involves reviewing medical records — does that mean there's no experimental treatment involved, and if so, what would my actual participation look like day-to-day?
2Since this trial is not yet recruiting, how long might it realistically be before it opens, and is waiting for it a reasonable option given where my lung cancer stands right now?
3The study is tracking whether patients are being diagnosed at early stages like Stage I or II versus late Stage IV — does my current diagnosis stage affect whether my doctor thinks this kind of study would even be relevant to my care?
4Because this is an observational study with no assigned treatment, would joining it affect my access to standard lung cancer treatments, or could I pursue both at the same time?
5Since this study focuses on describing patterns in how lung cancer is diagnosed across different countries, what would my doctor say are the direct benefits — if any — to me personally as a participant, versus the benefits being mainly for future patients?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.